Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx

Laryngoscope

Volumn 109, Issue 8, 1999, Pages 1329-1333

  Venkatesan, T K ^a,c   Kuropkat, Christiane ^b   Caldarelli, David D ^a   Panje, William R ^a   Hutchinson Jr , James C ^a   Chen, Shande ^a   Coon, John S ^a  

^a RUSH MEDICAL COLLEGE   (United States)

^b RUSH CANCER INSTITUTE   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Immunohistochemistry; Oral cavity; P27; Squamous cell carcinoma

Indexed keywords

PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOUTH CARCINOMA; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL MOVEMENT; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP-BINDING PROTEINS; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MOUTH NEOPLASMS; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0032775871     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-199908000-00029     Document Type: Article

References (14)

1. Alvi A, Myers EN, Johnson JT. Cancer of the oral cavity. In: Myers EN, Suen JY, eds. Cancer of the Head and Neck. Philadelphia: WB Saunders; 1996:321-360.
2. Hunter T, Pines J. Cyclins and cancer, II: cyclin D and cdk inhibitors come of age. Cell 1994;79:573-582.
3. Jordan RCK, Bradley G, Slingerland J. Reduced levels of the cell-cycle inhibitor p27 in epithelial dysplasia and carcinoma of the oral cavity. Am J Pathol 1998;142(2):585-590.
4. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27 protein: prognostic implications in primary breast cancer. Nature Med 1997; 3(2):227-230.
5. Alessandrini A, Chiaur DS, Pagano M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 1997;11:342-345.
6. Kawamata N, Morosetti R, Miller CW, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995;55:2266-2269.
7. Tsihlias J, Kapusta LR, DeBoer G, et al. Loss of cyclin-dependent kinase inhibitor p27 is a novel prognostic factor in localized prostate adenocarcinoma. Cancer Res 1998;58: 542-548.
8. KIP1 in lymphoid tissue. Am J Pathol 1997;151(1):151-160.
9. Pagano M, Tam SW, Theodoras AM, et al. Role of ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269: 682-685.
10. Steeg PS, Abrams JS. Cancer prognostics: past, present and p27. Nature Med 1997;3(2):152-154.
11. Katayose Y, Kim M, Rakkar ANS, Li Z, Cowan KH, Seth P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997;57: 5441-5445.
12. Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27 display increased body size, multiple organ hyperplasia, retina dysplasia and pituitary tumors. Cell 1996;85: 707-721.
13. Kiyokawa H, Kineman R, Manova-Todorova K, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27. Cell 1996;85:721-732.
14. Fero M, Rivkin M, Tasch M, et al. A syndrome of multi-organ hyperplasia with features of gigantism, tumorigenesis and female sterility in p27 deficient mice. Cell 1996;85: 733-744.